Achilles Therapeutics (Achilles Therapeutics) EV-to-Revenue : (As of Apr. 30, 2024)

Achilles Therapeutics EV-to-Revenue Chart

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Achilles Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Achilles Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achilles Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achilles Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Achilles Therapeutics's EV-to-Revenue falls into.

Achilles Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Achilles Therapeutics's EV-to-Revenue for today is calculated as:

Achilles Therapeutics's current Enterprise Value is $-95.39 Mil.
Achilles Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achilles Therapeutics  (NAS:ACHL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Achilles Therapeutics's PS Ratiofor today is calculated as:

Achilles Therapeutics's share price for today is $0.7698.
Achilles Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achilles Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Achilles Therapeutics (Achilles Therapeutics) Business Description